BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26070556)

  • 1. Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.
    Müller K; Henke G; Pietschmann S; van Gool S; De Vleeschouwer S; von Bueren AO; Compter I; Friedrich C; Matuschek C; Klautke G; Kortmann RD; Hundsberger T; Baumert BG
    J Neurooncol; 2015 Sep; 124(2):325-32. PubMed ID: 26070556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.
    De Vleeschouwer S; Ardon H; Van Calenbergh F; Sciot R; Wilms G; van Loon J; Goffin J; Van Gool S
    Cancer Immunol Immunother; 2012 Nov; 61(11):2105-12. PubMed ID: 22565485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.
    Palmer JD; Siglin J; Yamoah K; Dan T; Champ CE; Bar-Ad V; Werner-Wasik M; Evans JJ; Kim L; Glass J; Farrell C; Andrews DW; Shi W
    J Neurooncol; 2015 Sep; 124(2):215-21. PubMed ID: 26024653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Review of Re-irradiating Patients' Recurrent High-grade Gliomas.
    Klobukowski L; Falkov A; Chelimo C; Fogh SE
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):563-570. PubMed ID: 29891395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
    Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
    J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis.
    Niyazi M; Adeberg S; Kaul D; Boulesteix AL; Bougatf N; Fleischmann DF; Grün A; Krämer A; Rödel C; Eckert F; Paulsen F; Kessel KA; Combs SE; Oehlke O; Grosu AL; Seidlitz A; Lattermann A; Krause M; Baumann M; Guberina M; Stuschke M; Budach V; Belka C; Debus J
    Radiother Oncol; 2018 Apr; 127(1):121-127. PubMed ID: 29433917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
    Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
    Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of a prognostic model estimating the survival of patients with recurrent high-grade gliomas after reirradiation.
    Müller K; Henke G; Compter I; von Bueren AO; Friedrich C; Janssens G; Kramm CM; Hundsberger T; Paulsen F; Kortmann RD; Zwiener I; Baumert BG
    Pract Radiat Oncol; 2015; 5(3):e143-e150. PubMed ID: 25424325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort.
    Scholtyssek F; Zwiener I; Schlamann A; Seidel C; Meixensberger J; Bauer M; Hoffmann KT; Combs SE; von Bueren AO; Kortmann RD; Müller K
    Radiat Oncol; 2013 Jul; 8():161. PubMed ID: 23822643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of an established prognostic score after re-irradiation of recurrent glioma.
    Kessel KA; Hesse J; Straube C; Zimmer C; Schmidt-Graf F; Schlegel J; Meyer B; Combs SE
    Acta Oncol; 2017 Mar; 56(3):422-426. PubMed ID: 28075197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose salvage re-irradiation in recurrent/progressive adult diffuse gliomas: development of a novel prognostic scoring system.
    Maitre M; Gupta T; Maitre P; Chatterjee A; Dasgupta A; Moiyadi A; Shetty P; Epari S; Sahay A; Patil V; Krishnatry R; Sastri GJ; Jalali R
    Cancer Radiother; 2022 Nov; 26(8):994-1001. PubMed ID: 35715356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma.
    Combs SE; Edler L; Rausch R; Welzel T; Wick W; Debus J
    Acta Oncol; 2013 Jan; 52(1):147-52. PubMed ID: 22686472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
    Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
    J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis.
    Pinzi V; Orsi C; Marchetti M; Milanesi IM; Bianchi LC; DiMeco F; Cuccarini V; Farinotti M; Ferroli P; Finocchiaro G; Franzini A; Fumagalli M; Silvani A; Fariselli L
    Neurol Sci; 2015 Aug; 36(8):1431-40. PubMed ID: 25805705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK).
    Combs SE; Niyazi M; Adeberg S; Bougatf N; Kaul D; Fleischmann DF; Gruen A; Fokas E; Rödel CM; Eckert F; Paulsen F; Oehlke O; Grosu AL; Seidlitz A; Lattermann A; Krause M; Baumann M; Guberina M; Stuschke M; Budach V; Belka C; Debus J; Kessel KA
    Cancer Med; 2018 May; 7(5):1742-1749. PubMed ID: 29573214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
    Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
    Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.
    Fleischmann DF; Jenn J; Corradini S; Ruf V; Herms J; Forbrig R; Unterrainer M; Thon N; Kreth FW; Belka C; Niyazi M
    Radiother Oncol; 2019 Sep; 138():99-105. PubMed ID: 31252301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.
    Back M; Gzell CE; Kastelan M; Guo L; Wheeler HR
    Neurooncol Pract; 2015 Mar; 2(1):48-53. PubMed ID: 26034641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas.
    Heo J; Kim SH; Oh YT; Chun M; Noh OK
    Neoplasma; 2017; 64(5):803-808. PubMed ID: 28592133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.
    Flieger M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; la Fougère C; Ertl L; Linn J; Herrlinger U; Belka C; Niyazi M
    J Neurooncol; 2014 Apr; 117(2):337-45. PubMed ID: 24504501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.